MEXICO CITY. – The efficacy of a new drug to fight a disease goes beyond health; financial markets and the economy are also moving. This is the case with the news that showed the efficacy of plitidepsin.
The Spanish company PharmaMar developed the drug plitidepsin, which has been confirmed by the prestigious US magazine Science as a “powerful” alternative to SARS-CoV-2, which has managed to reduce the viral load of covid-19 by up to 99 percent.
From this news, not only PharmaMar rose more than 21.1% in the stock market, but also IBEX 35, the main reference stock index in the Spanish stock market, jumped 0.86% at the end of Tuesday.
Movement in the bag
PharmaMar titles are up 21.14% to € 106.3, after the scientific journal ‘Science’ confirms the ‘potent’ activity of plitidepsin against SARS-CoV-2. In two different animal models of SARS-CoV-2 infection, the assay showed reduced viral replication, resulting in a 99% decrease in lung viral loads in plitidepsin-treated animals.
“We believe that our data and the first positive results from the PharmaMar clinical trial suggest that plitidepsin should be seriously considered to expand clinical trials for the treatment of Covid-19,” emphasized the study presented by the pharmaceutical company. .
With information from Europa Press.
You can also read:
Biden plans to purchase more than 100 million covid-19 vaccines
Wings to fly: IMF foresees a 4.3% recovery in Mexico’s GDP
Boris Johnson is taking full responsibility for the covid-19 crisis in the UK